Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Soon Present Criteria for Drugs Subject to Optimal Use Guidelines
June 30, 2017
- MHLW Issues Notification to Redefine “Three Officer System” at Drug Makers
June 29, 2017
- Yamamoto Chemical Slapped with 22-Day Biz Suspension
June 29, 2017
- JMA’s Nakagawa Wants Clear Definitions for Original Drug, LLP, AG, Gx: Chuikyo
June 29, 2017
- “CEA” Scheme to Be Initially Introduced for Post-Listing Price Adjustment, Targeting Innovative Products with Big Market: Chuikyo
June 29, 2017
- Chuikyo Agrees to “Reward Innovation More” when Using Cost Calculation Pricing Method
June 29, 2017
- PMDA’s Review-Related Ordinary Loss Nearly Doubled in FY2016
June 28, 2017
- MHLW Calls for Drafting Guidelines on Polypharmacy in the Elderly
June 27, 2017
- 6 APIs Added to List of “Switch OTC” Candidates: MHLW
June 26, 2017
- MHLW Redefines Drug Makers’ 3 Key Officer System
June 26, 2017
- Boxed Warning to Be Erased from Label of Pfizer Smoking Cessation Aid Champix
June 26, 2017
- Emergency Stockpile of Anti-Influenza Drugs to Be Reduced to Enough for 47.7 Million People
June 26, 2017
- 670 Codeine, Tramadol Medicines to Be Contraindicated for Kids under 12
June 23, 2017
- Wakayama Substance Supplier Mixed in China-Made Ingredient; MHLW Sees No Safety Concerns
June 23, 2017
- 3 Independent Administrative Agencies Will Have Access to Research Funding from Outside Initial Budgets
June 23, 2017
- Pharmaceuticals, Medical Devices Unlikely to Be Focus of Japan-EU EPA
June 22, 2017
- Draft Guideline on Lifecycle Management Reaches Agreement at ICH Meeting in Montreal
June 22, 2017
- JMA Plans Chuikyo Rep Reshuffle, Nakagawa Likely to Bow Out
June 21, 2017
- PMDA Beats FY2016 Review Time Targets
June 16, 2017
- CDISC-Based Electronic Submissions for 24 Products in FY2016: PMDA
June 16, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…